Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction

European Journal of Heart Failure

Volumn 20, Issue 7, 2018, Pages 1139-1145

  Abdul Rahim, Azmil H ^a   Shen, Li ^b   Rush, Christopher J ^b   Jhund, Pardeep S ^b   Lees, Kennedy R ^b   McMurray, John J V ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Digoxin; Heart failure with mid range ejection fraction; Outcome

Indexed keywords

DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; NITRATE; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; CARDIOTONIC AGENT;

ADULT; AGE; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART FAILURE; HEART FAILURE WITH MIDRANGE EJECTION FRACTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPERTENSION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX; TREATMENT OUTCOME; AGED; CLINICAL TRIAL; DOSE RESPONSE; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR;

AGED; CARDIOTONIC AGENTS; DIGOXIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 85042592467     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.1160     Document Type: Article

References (17)

1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975.
2. Bayes-Genis A, Nunez J, Lupon J. Heart failure with mid-range ejection fraction: a transition phenotype? Eur J Heart Fail 2017;19:1635–1637.
3. Hsu JJ, Ziaeian B, Fonarow GC. Heart failure with mid-range (borderline) ejection fraction: clinical implications and future directions. JACC Heart Fail 2017;5:763–771.
4. Lam CS, Solomon SD. Fussing over the middle child: heart failure with mid-range ejection fraction. Circulation 2017;135:1279–1280.
5. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525–533.
6. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, Love TE, Aronow WS, Adams KF Jr, Gheorghiade M. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary Digitalis Investigation Group trial. Circulation 2006;114:397–403.
7. The Virtual International Cardiovascular and Cognitive Trials Archive (VICCTA). http://www.viccta.org/ (25 September 2017).
8. Guyler P. News from the 23rd European Stroke Conference. British Journal of Cardiology 2014;21:102.
9. Royston P, Sauerbrei W. A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. Stat Med 2004;23:2509–2525.
10. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, Parissis J, Laroche C, Piepoli MF, Fonseca C, Mebazaa A, Lund L, Ambrosio GA, Coats AJ, Ferrari R, Ruschitzka F, Maggioni AP, Filippatos G. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19:1574–1585.
11. Pascual-Figal DA, Ferrero-Gregori A, Gomez-Otero I, Vazquez R, Delgado-Jimenez J, Alvarez-Garcia J, Gimeno-Blanes JR, Worner-Diz F, Bardaji A, Alonso-Pulpon L, Gonzalez-Juanatey JR, Cinca J. Mid-range left ventricular ejection fraction: clinical profile and cause of death in ambulatory patients with chronic heart failure. Int J Cardiol 2017;240:265–270.
12. Lund L. Candesartan provides similar benefit for patients with mid-range ejection fraction as those with reduced ejection fraction. https://www.escardio.org/Congresses-&-Events/Heart-Failure/Congress-resources/candesartan-provides-similar-benefit-for-patients-with-mid-range-ejection-fracti/ (25 September 2017).
13. Lund L. Phenotype HF with midrange EF resembles HFrEF, albeit with better outcomes. https://pace-cme.org/2017/04/30/phenotype-hf-with-midrange-ef-resembles-hfref-albeit-with-better-outcomes/ (25 September 2017).
14. Sartipy U, Dahlstrom U, Fu M, Lund LH. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail 2017;5:565–574.
15. Cleland JG, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJ, Manzano L, McMurray JJ, Ruschitzka F, van Veldhuisen DJ, von Lueder TG, Böhm M, Andersson B, Kjekshus J, Packer M, Rigby AS, Rosano G, Wedel H, Hjalmarson Å, Wikstrand J, Kotecha D; Beta-blockers in Heart Failure Collaborative Group. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018;39:26–35.
16. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O'Meara E, Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer MA; TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 2016;37:455–462.
17. Rastogi A, Novak E, Platts AE, Mann DL. Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction. Eur J Heart Fail 2017;19:1597–1605.